Manufacturing Contracts for Pfizer Revealed by Samsung Biologics

The latest deals will see the biotech division of the Samsung Group produce biosimilar products ranging from oncology and inflammation to immunotherapy in the period to 2029 at its new Plant 4 in South Korea.

The groups biotech department will produce similar goods at its new South Korea Plant 4 facility until 2029, encompassing everything from immunotherapy to oncology and inflammation.

Samsung biologics disclosed that “the latest orders bring this year’s combined tally of orders from Pfizer to $1.08 billion.”

A $704 million contract, and a supplementary order of $193 million, are both components of an agreement that came to light in earlier this year.

The agreements were embraced by Samsung as a positive next step in their strategic alliance.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.